Peer-reviewed veterinary case report
Repeated radiotherapy outcomes for dogs with recurring nasal tumors
By Ueno, Hirona et al.·Published in Open veterinary journal·2025·School of Veterinary Medicine, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Clinical outcomes and prognostic factors of repeated conventional hypofractionated radiotherapy for recurrent intranasal tumors in dogs.
- Species:
- dog
Plain-English summary
A group of dogs with recurrent intranasal tumors, which are often difficult to treat, received repeated courses of a specific type of radiation therapy called hypofractionated re-irradiation (re-RT) after their initial treatment. Out of 30 dogs studied, many had a type of cancer called adenocarcinoma. The dogs that underwent more than one course of re-RT lived significantly longer than those who only had one course, with some surviving over two years after treatment. While there were some mild side effects like hair loss and cataracts, the overall prognosis improved with repeated treatments, making this a promising option for dogs with these tumors.
People also search for: dog intranasal tumor treatment · hypofractionated radiation therapy for dogs · recurrent dog cancer survival rates
Abstract
BACKGROUND: Despite an initial favorable response to hypofractionated radiotherapy (RT), intranasal neoplasia has a poor long-term prognosis. Re-irradiation (re-RT) has been shown to result in clinical remission in dogs with recurrent intranasal tumors. Hypofractionated re-RT is indicated in cases of recurrence. AIM: This study aimed to investigate the response of patients with recurrent intranasal tumors who were initially treated with repeated hypofractionated RT and subsequently underwent re-RT. METHODS: Medical records of dogs with intranasal tumors that relapsed after undergoing hypofractionated RT at Azabu University Veterinary Teaching Hospital and who underwent re-RT between 2008 and 2022 were retrospectively analyzed. RESULTS: Among the 30 dogs included, 20 had adenocarcinomas. Eleven patients underwent a second re-RT, and five patients underwent a third re-RT. The median total isocenter dose and total number of fractions were 56 Gy (range, 37.5-102) and 8 fractions (range, 5-14), respectively. The first, second, and third progression-free intervals (PFIs) were 315 (= 30), 185 (= 11), and 218 days (= 4), respectively. Overall survival (OS) was 504 days (= 30). Adverse events such as alopecia (= 7), white hair (= 8), cataracts (= 9), pigmentation (= 5), keratitis (= 3), and corneal ulceration (= 1) were limited to grades 1 and 2. The medians of the first PFI for one course and two or more courses of re-RT were 298 and 331 days, respectively, indicating no significant differences between the groups. The OS after two or more courses of re-RT (758 days) was significantly longer than after one course of re-RT alone (414 days) (= 0.048). However, the cases were not randomized, and most of the tumor types were adenocarcinomas. CONCLUSION: Since it is expected to prolong survival time with few life-threatening adverse events, the findings of the present study suggest that hypofractionated re-RT can be used in dogs with recurrent intranasal tumors initially treated with hypofractionated RT. Therefore, repeated hypofractionated re-RT may be a reasonable option for young dogs with a good initial response and recurrent intranasal tumors.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40201825/